Since estrogen and some selective estrogen receptor modulators have been suggested as possible therapeutic options for PD (30), identification of the molecular mechanism of participation of DSCAM-AS1 in the pathetiology of PD has clinical significance. The gene discussed is DSCAM; the disease is Parkinson disease.